WHO Issues Warning Over Acute Lack of Obesity Jabs

Fewer than 10% of people that would benefit from weight-loss injections like Wegovy are able to get them, states the WHO as it issues its initial guidance on the therapies.

Given in excess of 1,000,000,000 people worldwide now living with obesity, it is calling for broader and more equitable access to these injectable treatments.

Per forecasts, over two billion could be obese by 2030 without intervention.

"The latest guidance acknowledges that excess weight is a chronic disease that can be addressed with holistic and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and distribution challenges are major barriers to broad access to the jabs that can assist patients in reducing considerable weight, explains the body.

Weight-Loss Drug Supply Crisis

Even in the present most favorable scenario, the supply of such drugs would only suffice for around 100 million people – less than 10% of those who need them, per the health organization.

The recommendation calls on nations and manufacturers to increase availability, through approaches like patent sharing.

A patent on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.

How Weight-Loss Drugs Function

GLP-1 drugs mimick a natural hormone to delay gastric emptying, reduce hunger and increase satiety so people consume fewer calories.

People usually begin shedding pounds in the initial weeks of beginning the weekly injections.

Evidence suggests users may put most of the weight back on a year later of discontinuing the treatment, as their typical food cravings resume.

To be overweight or obese elevates your likelihood for contracting diseases, including type 2 diabetes, cardiovascular issues, stroke, and certain cancers.

Obesity affects people in every country and was linked to 3.7 million fatalities worldwide in 2024, per the WHO.